Table 3. Hazards for Any Relapses (Any Localization) and Neurologic Relapses According to Immunosuppressive or Immunomodulatory Treatments.
| Treatment | No. of Relapses/Therapeutic Sequences | HR (95%CI) | P Value |
|---|---|---|---|
| Any relapsea | |||
| None | 38/87 | 1 [Reference] | NA |
| Glucocorticoid alone | 85/254 | 0.59 (0.39 to 0.90) | .01 |
| Methotrexate sodium | 44/125 | 0.48 (0.29 to 0.79) | .004 |
| Azathioprine sodium | 8/14 | 1.40 (0.55 to 3.53) | .48 |
| Hydroxychloroquineb | 16/59 | 0.29 (0.14 to 0.63) | .002 |
| Mycophenolic acid | 26/64 | 0.67 (0.37 to 1.23) | .20 |
| Intravenous cyclophosphamide | 11/120 | 0.18 (0.09 to 0.37) | <.001 |
| Infliximab | 4/28 | 0.31 (0.11 to 0.82) | .02 |
| Neurologic relapsec | |||
| None | 20/87 | 1 [Reference] | NA |
| Glucocorticoid alone | 58/254 | 0.68 (0.38 to 1.23) | .20 |
| Methotrexate | 26/125 | 0.47 (0.25 to 0.87) | .02 |
| Azathioprine | 6/14 | 1.88 (0.69 to 5.14) | .22 |
| Hydroxychloroquineb | 12/59 | 0.37 (0.15 to 0.92) | .03 |
| Mycophenolic acid | 14/64 | 0.58 (0.25 to 1.34) | .20 |
| Intravenous cyclophosphamide | 10/120 | 0.26 (0.11 to 0.59) | .001 |
| Infliximabd | 1/28 | 0.16 (0.021 to 1.24) | .08 |
Abbreviations: HR, hazard ratio; NA, not applicable.
a
Analysis was stratified on period of neurosarcoidosis (NS) diagnosis (1990-1999 vs 2000-2015).
b
Includes alone (n = 15), combined with corticosteroids (n = 30), or combined with corticosteroids plus methotrexate (n = 15).
c
Calculated as cause-specific HRs for neurologic relapse; analysis was stratified on period of NS diagnosis (1990-1999 vs 2000-2015).
d
For infliximab, the very low number with neurologic relapse should be emphasized and the HR interpreted with caution.